Volume : 09, Issue : 05, May – 2022

Title:

09.UNDERSTANDING OSTEOPOROSIS, IT’S RISK, PREVENTION AND TREATMENT
‬

Authors :

Patil Gayatri, Shevkar Pranav , Wankhade Pavankumar*

Abstract :

Osteoporosis refers to porous bone which is an ailment wherein the bones become weak and delicate, brittle from loss of tissue, typically because of hormonal changes, or lack of calcium or vitamin D. Estrogen and Calcium deficiency,Poor nutrition,Malabsorption, Amenorrhea, Inactive lifestyle, Female gender, Smoking, Hyperthyroidism could be the main factors responsible for osteoporosis. Signs and symptoms of osteoporosis include tenderness or bone pain, loss of height overtime, neck or lower back pain due to fractures,etc More than 200 million individuals worldwide suffer from osteoporosis, and the prevalence of the disease increases as people age. Bone density is directly affected due to hormonal changes that happens at menopause due to which women are at high risk than men for developing osteoporosis. Inability to reach peak bone mass and the Imbalance of bone absorption and formation are some combination factors that can result into osteoporosis. Bone Mineral Density(BMD) Measurement, Clinical risk factors and fracture risk assessment, Fracture Risk Assessment Tool (FRAX) can be used to diagnose the disease. The various kinds of models of osteoporosis are also been described in this article of osteoporosis.The treatment for osteoporosis includes biphosphates, Menopausal Hormone Therapy (MHT), Selective oestrogen receptor modulators (SERM), Denosumab, Anabolics like Teriparatide, Abaloparatide and Romosozumab.
Key Words: Osteoporotic fracture, Osteoporosis, Epidemiology, Osteoporosis management, Bone mineral density, Fracture risk.

Cite This Article:

Please cite this article in press Wankhade Pavankumar et al, Understanding Osteoporosis, It’s Risk, Prevention And Treatment., Indo Am. J. P. Sci, 2022; 09(5).,

Number of Downloads : 10

References:

1. Cummings S.R.Melton 3rd, L.J.Epidemiology and outcomes of osteoporotic fractures.Lancet. 2002; 359: 1761-1767.
2. Burge R, Dawson-Hughes B, Solomon D, et al. Incidence and economic burden or osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475.
3. Cosman F, de Beur S, LeBoff M, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. Erratum in: Osteoporos Int 2015;26(7)2045–2047.
4. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. Am Fam Physician. 2015;92(4):261–268.
5. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Journal Clin Invest. 2005;115(12):3318–3325.
6. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54.
7. Hunter DJ, Sambrook PN. Bone loss: epidemiology of bone loss. Arthritis Res. 2000;2(6):441–445.
8. NIH Osteoporosis and Related Bone Diseases National Resource Center. The Surgeon General’s report on bone health and osteoporosis: what it means to you. Dec, 2015. [Accessed June 6, 2017].
9. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Journal Clin Invest. 2005;115(12):3318–3325.
10. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. EndocrPract. 2016;
11. Cosman F, de Beur S, LeBoff M, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. Erratum in: Osteoporos Int 2015;26(7)2045–2047.
12. Qaseem A, Forciea MA, McLean RM, et al. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017:1–27.
13. Gourlay ML, Fine JP, Preisser JS, et al. Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366(3):225–233.
14. Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA. 2013;310(12):1256–1262.
15. Briot K, Roux CGlucocorticoid-induced osteoporosisRMD Open 2015;
16. Ganesh V.HaladeMdM.RahmanPaulJ.WilliamsGabrielFernandesThe Journal of Nutritional Biochemistry Volume 21, Issue 12, December 2010.
17. Joana T. Rosa, Vincent Laize Fish Models of Induced Osteoporosis Front. Cell Dev. Biol., 10 June 2021
18. Matthew T. Drake, MD, PhD, Bart L. Clarke, MD, and Sundeep Khosla, MD Bisphosphonates: Mechanism of Action and Role in Clinical Practice 2009 Sep
19. Bjarnason, N.H., C. Hassager, and C. Christiansen, Postmenopausal bone remodelling and hormone replacement. Climacteric, 1998. 1(1): p. 72-9.
20. Torgerson, D.J. and S.E. Bell-Syer, Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA, 2001. 285(22): p. 2891-7.
21. M Varenna et al. Reumatismo, The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis, Jul-Sep 2010.
22. Langdahl, B., S. Ferrari, and D.W. Dempster, Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis, 2016. 8(6): p. 225-235.
23. Shlomo Melmed MB ChB, MACP, in Williams Textbook of Endocrinology, Osteoporosis : Basic and Clinical Aspects 2020.
24. Osteoporosis: Asessing the risk of fragility fracture, ClInical Guideline (CG146);Published- 08 August,2012; Last updated-07 February, 2017.